Insider buying last 90 days
No open-market insider purchases were filed for LMRI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LMRI insider filing, plotted on the chart in Gekko.Open LMRI in Gekko
NASDAQ: LMRI
Lumexa Imaging (LMRI) Stock Analysis & Forecast
Oct 12 close
$10.68+0.14 (+1.3%)
Gekko Brief
AI summaryOct 12 closeThis week's attention on Lumexa Imaging centers on analyst coverage and comparative positioning rather than company-specific news. Truist Financial initiated coverage with a "buy" rating and an $18 price target, implying 74% upside, adding to a string of positive ratings. Separate commentary notes LMRI is projected by analyst consensus to reach profitability, with a projected profit of $34 million in 2026 after a 2025 loss, while another piece set LMRI alongside DocGo (DCGO) in a head-to-head comparison of small-cap healthcare names.
LMRI closed at $10.68, up 1.3%, but remains below both its 50-day ($11.27) and 200-day ($11.53) moving averages, with the 50-day below the 200-day. The stock sits in the Neutral zone of the GekkoIndex at a reading of 59.2, down 1.8 over the prior five sessions. Price stands 9.2% below Gekko Fair Value of $11.76.
The next earnings report is scheduled for 11 November 2026, 29 days out, placing it just beyond a typical 20-trading-day holding window. The prior quarter saw EPS of $0.02 against a $0.12 estimate, with a 20.8% reaction, underscoring sensitivity around results. No insider, Congress, or unusual options activity appears in the current window. Analyst sentiment remains uniformly bullish, with 8 of 8 covering firms rated buy and a consensus target of $17.67, implying 65.4% upside.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Lumexa Imaging price vs fair value
Close $10.68200-day averageGekko Fair Value $11.76
Lumexa Imaging quick facts
- Market cap
- $1.03B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.37
- Revenue, TTM
- $1.04B
- Profit margin
- -2.7%
- Dividend yield
- —
- Beta
- —
- Volume
- 185,449 avg 435,505
- 1-year return
- —
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±15.1%
- 50-day average
- $11.27
- 200-day average
- $11.53
- Next earnings
- Nov 11
- Shares outstanding
- 96.08M
Lumexa Imaging swing-trade checklist
Lumexa Imaging scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $10.68 is below the 50-day ($11.27) and 200-day ($11.53) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
59.2, Neutral
Reading 59.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
9.2% below
Price is 9.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Lumexa Imaging stock chart and price history
Lumexa Imaging closed at $10.68 on Oct 12, 2026, inside a 52-week range of $6.45 to $19.45.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.0%
- 3 months
- −2.1%
- 6 months
- +10.4%
The full LMRI chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LMRI in Gekko
Follow Lumexa Imaging through every session
Put LMRI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LMRI in GekkoFree for 7 days. No credit card required.
About Lumexa Imaging
Lumexa Imaging runs a network of outpatient diagnostic imaging centers located across the United States. Patients visiting these facilities can access advanced scanning procedures such as MRI, CT, and PET imaging, along with more routine diagnostic and screening work including X-rays, ultrasounds, and mammograms. The company is best known for bringing this full span of imaging services together under one operator in outpatient settings.
Its business centers on managing and operating these imaging sites rather than manufacturing equipment or software, with revenue tied to the diagnostic and screening procedures performed at its centers for patients seeking outpatient care.
Lumexa Imaging was founded in 2018 and is based in Raleigh, North Carolina. Its shares trade on the NASDAQ under the ticker LMRI.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- lumexaimaging.com
Lumexa Imaging GekkoIndex: the smart money zone
Lumexa Imaging’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.2, in the Neutral zone, down 1.8 points over five sessions.
59.2Neutral
Down 1.8 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 30 | +3.0% | +10.2% | ||
| Accumulation | 73 | −1.3% | −2.6% | ||
| Neutral (current zone) | 92 | −1.1% | −6.3% | ||
| Distribution | 8 | Too few readings yet | |||
| Selling | 0 | Not available | |||
Average LMRI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the LMRI price, zone by zone.Track LMRI in Gekko
Is Lumexa Imaging stock overvalued? Gekko Fair Value
Lumexa Imaging trades 9.2% below Gekko Fair Value of $11.76, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Lumexa Imaging shares are worth, recalculated every trading day.
$11.76
Gekko Fair Value, Oct 10, 2026
9.2% Undervalued
At the end of Aug 2026 the price was 8.7% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open LMRI in Gekko
Lumexa Imaging insider and Congress trading
No open-market insider purchases were filed for Lumexa Imaging, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LMRI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LMRI, plotted on the chart in Gekko.Open LMRI in Gekko
Buybacks
Lumexa Imaging has been buying back its own shares.
- Bought back, year ended Dec 31, 2023
- $118K
- As a share of market cap
- 0.01%
From company filings.
Lumexa Imaging earnings: next date and track record
Lumexa Imaging reports on Nov 11, 2026 (30 days away), and beat the EPS estimate in 0 of its last 1 report.
Next earnings report
Nov 11, 2026
30 days away
- EPS estimate
- $0.20
- Revenue estimate
- $270.3M
0 of 1reports beat the EPS estimate
±20.8%average move across the report
0 of 1reports followed by a gain
Last earnings call, May 12, 2026 AI summary
- What they said
- Lumexa reported Q1 2026 results in line with expectations, with consolidated revenue of $253 million, up 3% year-over-year (system-wide revenue up 4%). Advanced modalities were a key growth driver, up 7% year-over-year (PET +23.1%, MRI +8.2%). Management highlighted progress on strategic priorities: same-center growth, ramping de novo openings, two acquisitions (including the first IDTF in Pennsylvania as part of a JV with UPMC), opening two de novos, and leadership additions. Seasonality and four weather events produced an estimated $4 million EBITDA headwind in Q1 and temporarily affected volumes, but volumes recovered through March and advanced modalities rebounded fastest. Management reiterated confidence in the full-year outlook, emphasizing that earnings are back-end weighted (about 55% of adjusted EBITDA expected in H2), and noted strong ramp performance from recently opened de novos. Operational initiatives include deployment of FastScan (MRI acceleration), AI tools, virtual MRI, revenue-cycle automation, and rollouts of cash-pay services like breast arterial calcification. CapEx is expected at roughly $5–7 million per quarter. Management expressed confidence but acknowledged short-term headwinds from weather and seasonality and that some acquired sites will require optimization and will contribute modestly in 2026.
- Guidance
- Full-year 2026 guidance unchanged. Seasonality: management expects ~55% of adjusted EBITDA in the second half of the year (about a 100 basis point shift relative to prior spread assumptions). Q1 represented ~21.5% of annual adjusted EBITDA at midpoint; Q2 ~23.5%. CapEx guidance: ~$5–7 million per quarter (mid-to-upper $20Ms full year). Goal to open 8–10 de novo centers in 2026. Target FastScan penetration to just north of ~66–67% of MRI fleet by year-end. Management expects operating/free cash flow to accelerate in H2 (company commentary supports meaningful cash flow pickup in second half).
- Risks flagged
- Weather-related disruptions and enhanced seasonality can materially and unpredictably depress volumes and EBITDA (Q1 impact ~ $4 million). Ramp risk for de novo and acquired sites (acquisitions often require optimization and may have minimal contribution in 2026). Working capital timing and front-loaded benefit/bonus payments create weak early-year cash flow. Dependence on payer contracting and reimbursement dynamics (though management reported stability). Potential operational risks related to supply chains (e.g., radiotracer/isotope availability) were discussed by analysts though not flagged as immediate issues by management.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 12, 2026 | $0.02 est $0.12 | $252.5M est $249.5M | −20.8% |
| Dec 3, 2025 | −$0.03 | $260.1M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Lumexa Imaging stock forecast and analyst price targets
Analysts’ average 12-month price target for Lumexa Imaging is $17.67, +65.4% from the last close, from 8 firms rating the stock in the last 90 days.
$17.67consensus 12-month target, +65.4% from the last close
Now $10.68Avg $17.67
Low $13High $19
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Truist Financial | $18 | +68.5% |
| Sep 28 | Raymond James | $17 | +59.2% |
| Sep 25 | KeyBanc | $18 | +68.5% |
| Sep 24 | KeyBanc | $18 | +68.5% |
| Aug 28 | Barclays | $13 | +21.7% |
−6.3%average 20-day move after past Neutral readings
±4.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Lumexa Imaging market cap and key statistics
Lumexa Imaging’s market cap is $1.03B and revenue of $1.04B over the last twelve months.
Valuation
- Market cap
- $1.03B
- EPS, TTM
- −$0.37
- Gekko Fair Value
- $11.76
Trading
- Volume
- 185,449
- Avg volume, 20 days
- 435,505
- 52-week high
- $19.45
- 52-week low
- $6.45
- Shares outstanding
- 96.08M
Financials
- Revenue, TTM
- $1.04B
- Profit margin
- -2.7%
- Return on equity
- -12.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±15.1%
Lumexa Imaging stock news this week
3 headlines about Lumexa Imaging from the past week, newest first, each linking to the publisher.
- Lumexa Imaging (NASDAQ:LMRI) versus DocGo (NASDAQ:DCGO) Head-To-Head ComparisonDefense World, Oct 7
- Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Could Be Less Than A Year Away From ProfitabilitySimply Wall Street, Oct 6
- Truist Financial Begins Coverage on Lumexa Imaging (NASDAQ:LMRI)MarketBeat, Oct 5
Lumexa Imaging peers
Lumexa Imaging’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Lumexa Imaging stock FAQ
What is Lumexa Imaging’s market cap?
Lumexa Imaging’s market cap is $1.03B at the Oct 12, 2026 close of $10.68, with 96.08M shares outstanding.
What is the Lumexa Imaging stock forecast?
The consensus analyst 12-month price target for Lumexa Imaging is $17.67, +65.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Lumexa Imaging stock overvalued or undervalued?
On Gekko’s estimate Lumexa Imaging is undervalued: the Oct 12, 2026 close of $10.68 is 9.2% below Gekko Fair Value of $11.76. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Lumexa Imaging report earnings next?
Lumexa Imaging is expected to report on Nov 11, 2026 (30 days away). Analysts expect earnings of $0.20 per share on revenue of $270.3M.
What is Lumexa Imaging’s 52-week high and low?
Lumexa Imaging’s 52-week high is $19.45 and its 52-week low is $6.45; it closed at $10.68 on Oct 12, 2026.
Is Lumexa Imaging stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Lumexa Imaging the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.